Doubling golimumab doses did not improve skin disease in two obese patients with psoriatic arthritis

G Ital Dermatol Venereol. 2017 Dec;152(6):670-672. doi: 10.23736/S0392-0488.16.05338-4.

Authors

Claudio Bonifati¹, Viviana Lora², Dario Graceffa²

Affiliations

¹ Center for the Study and Treatment of Psoriasis, San Gallicano Dermatologic Institute for Research and Care, Rome, Italy - psoriasi@ifo.it.
² Center for the Study and Treatment of Psoriasis, San Gallicano Dermatologic Institute for Research and Care, Rome, Italy.

PMID: 29050449
DOI: 10.23736/S0392-0488.16.05338-4

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal / administration & dosage*
Arthritis, Psoriatic / complications
Arthritis, Psoriatic / drug therapy*
Dose-Response Relationship, Drug
Drug Substitution
Humans
Male
Methotrexate / therapeutic use
Middle Aged
Obesity / complications
Treatment Failure
Ustekinumab / therapeutic use

Substances

Antibodies, Monoclonal
golimumab
Ustekinumab
Methotrexate